Thus, significant downregulation of LRRK2 after 2 months (−2.10‐fold, p = 8.54 × 10−6) and 6 months (−1.71‐fold, p = 9.38 × 10−4) of treatment suggests an autophagy‐inducing mechanism where sargramostim provides protective outcomes in PD. The gene discussed is LRRK2; the disease is Parkinson disease.